Hepatitis B can be deadly, but whether it poses a serious threat depends heavily on when you were infected, whether the infection becomes chronic, and whether it’s detected and treated. In 2022, hepatitis B caused an estimated 1.1 million deaths worldwide, mostly from cirrhosis and liver cancer. The good news: most adults who contract the virus recover completely, and effective treatments exist for those who develop chronic infection.
Acute Infection: Low Risk but Not Zero
When adults first contract hepatitis B, roughly 95% recover fully within a few weeks to months. Their immune system clears the virus, and they develop lifelong immunity. For most people, acute hepatitis B is a temporary illness with symptoms like fatigue, nausea, and jaundice that resolve on their own.
The rare danger is fulminant hepatitis, a sudden and severe form of liver failure that occurs in about 1% of acute infections. When it does happen, it’s extremely serious, with a mortality rate near 70%. This is uncommon enough that most people with acute hepatitis B never face it, but it’s the reason severe symptoms like confusion, extreme fatigue, or worsening jaundice during an acute infection require emergency medical attention.
Chronic Infection Is Where the Real Danger Lies
Hepatitis B becomes life-threatening primarily when it turns chronic, meaning the virus stays in your body for six months or longer. A chronic infection silently damages the liver over years or decades, and many people have no symptoms until serious complications develop.
Over a 10-year period, about 16% of people with chronic hepatitis B develop cirrhosis (severe scarring of the liver), and about 8% develop liver cancer. If cirrhosis is already present, the risk of liver cancer climbs sharply: roughly 30% over 10 years. These two complications, cirrhosis and liver cancer, account for the vast majority of hepatitis B deaths globally.
Age at Infection Changes Everything
The single biggest factor determining whether hepatitis B becomes dangerous is the age at which you were infected. This is counterintuitive: the younger you are when infected, the worse the long-term outlook.
About 90% of infants infected with hepatitis B develop chronic infection. For children between ages 1 and 5, that number drops to around 30%. Adults have it the other way around: fewer than 5% of adults who contract the virus become chronically infected. This is why hepatitis B vaccination at birth is so critical. Infants can’t fight off the virus the way adults can, and a chronic infection acquired in infancy means decades of liver damage before symptoms ever appear.
Co-infection With Hepatitis D
Hepatitis D only infects people who already have hepatitis B, and the combination is significantly more dangerous. A study of U.S. veterans found that people co-infected with both viruses who weren’t receiving treatment had nearly double the death rate compared to those with hepatitis B alone (5.14 versus 2.98 deaths per 100 person-years). Treatment for hepatitis B appeared to close much of that gap, bringing the mortality rate for co-infected individuals down to 3.0 per 100 person-years.
Treatment Dramatically Improves Survival
Antiviral treatment for chronic hepatitis B isn’t a cure. The virus typically can’t be fully eliminated from the body. But long-term treatment suppresses the virus enough to slow or prevent liver damage, and the survival benefits are substantial.
For people with decompensated cirrhosis, one of the most advanced stages of liver disease, the contrast is stark. Without antiviral treatment, the five-year survival rate historically ranged from just 14% to 35%. With treatment, that number jumps to around 67%. The rates of liver cancer and death drop sharply after the first year of antiviral therapy. For people with chronic hepatitis B who haven’t yet developed cirrhosis, starting treatment earlier offers even better outcomes, reducing the risk of ever progressing to cirrhosis, liver cancer, or liver failure.
Why Screening Matters So Much
The biggest problem with hepatitis B isn’t a lack of treatment. It’s that many people don’t know they’re infected. Chronic hepatitis B is often completely silent for 20 or 30 years. By the time symptoms appear, the liver may already be severely damaged.
CDC modeling estimates that universal screening of adults would prevent about 10 hepatitis B-related deaths, 5.5 cases of liver cancer, and 7.4 cases of cirrhosis for every 100,000 people screened. In higher-risk populations like those seen in STI clinics, the numbers are even more dramatic: 163 deaths and 90 cases of liver cancer prevented per 100,000 people screened. A simple blood test is all it takes, and the CDC now recommends that every adult be tested at least once.
Vaccination Nearly Eliminates the Risk
The hepatitis B vaccine is one of the most effective tools in medicine for preventing a deadly disease. Taiwan, which launched universal infant vaccination in 1984, saw liver cancer rates in children drop by 62% to 70% within about 15 years. In one region of China, vaccination provided 84% protection against liver cancer. Global modeling suggests that if 90% of the world’s population received the full three-dose vaccine series, it would prevent 84% of all hepatitis B-related deaths from cirrhosis and liver cancer.
For anyone who hasn’t been vaccinated, the vaccine is safe and effective at any age. Three doses over six months provide long-lasting protection, and for most people, immunity lasts decades or longer.